On February 25, 2015, the FDA approved Toujeo—a long-acting insulin indicated to improve sugar control in adults with type 1 and type 2 diabetes.
When will Toujeo be available?
According to the manufacturer, Sanofi-Aventis, Toujeo will be available at the beginning of the second quarter in 2015.
What is long-acting insulin?
Long-acting insulin can also be referred to as basal insulin. Long-acting insulin lowers blood sugar levels slowly and evenly for up to 24 hours. This means that Toujeo manages blood sugar between meals and at nighttime.
Are there other long-acting insulins available?
Is Toujeo similar to any of the other long-acting insulins?
What are the side effects of Toujeo?
The most common side effects associated with Toujeo are hypoglycemia, allergic reaction, injection site reaction, loss of body fat at injection sites, itching, rash, edema, weight gain.